Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Diabetes Care

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.25.5.869PMID 11978683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.

  2009cited by this paper
• Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats.

  2001cited by this paper
• Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

  2000cited by this paper
• Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

  2000cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cited by this paper
• Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

  1999cited by this paper
• NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.

  1999cited by this paper
• Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: A link to neurogenic skin disorders.

  1999cited by this paper
• Glucagon‐like peptide‐1 (GLP‐1): A gut hormone of potential interest in the treatment of diabetes

  1998cited by this paper
• Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

  1998cited by this paper
• Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.

  1998cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

  1998cited by this paper
• Glucagon-Like Peptides

  1998cited by this paper
• Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

  1997cited by this paper
• GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions

  1997cited by this paper
• The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients

  1996cited by this paper
• Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.

  1996cited by this paper
• Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM

  1996cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

  1995cited by this paper
• Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

  1994cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper

• Synthetic Approaches to Novel DPP-IV Inhibitors—A Literature Review

  2025cites this paper
• Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus

  2025cites this paper
• Dipeptidyl Peptidase-4 Inhibitors Improved Lipid Levels in Patients With Type 2 Diabetes: A Meta-analysis of Randomized Clinical Trials.

  2025cites this paper
• Semaglutide: Multilevel organ protection in type 2 diabetes – from the heart and kidneys to peripheral vessels

  2025cites this paper
• Exploring DPP-4: Implications in diverse diseases and structural insights for novel inhibitor design.

  2025cites this paper
• Contribution of amino acids in the active site of dipeptidyl peptidase 4 to the catalytic action of the enzyme

  2024cites this paper
• The impact of growth hormone (GH) therapy on glucose metabolism: A narrative review mainly focused on GH-deficient (GHD) children and adolescents

  2024cites this paper
• Angular-Substituted [1,4]Thiazino[3,4-a]Isoquinolines: Biological Evaluation and In Silico Studies on DPP-IV Inhibition

  2024influential citation
• Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats

  2024cites this paper
• DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice

  2023cites this paper
• Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs

  2023cites this paper
• Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

  2023cites this paper
• Development of sandwich ELISAs for detecting glucagon-like peptide-1 secretion from intestinal L-cells and their application in STC-1 cells and mice

  2022cites this paper
• The Role of incretin-based therapies in maintaining glucose homeostasis and management of diabetes mellitus

  2022cites this paper
• Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

  2022cites this paper
• Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis

  2022cites this paper
• Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology

  2022cites this paper
• Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition

  2021cites this paper
• Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.

  2021cites this paper
• Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidase–4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial

  2020cites this paper
• Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

  2020cites this paper
• A First Attempt to Identify Repurposable Drugs for Type 2 Diabetes: 3D-Similarity Search and Molecular Docking

  2020cites this paper
• Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans

  2020cites this paper
• On Meal Effects and DPP-4 Inhibition Islet- and Incretin Hormones in Health and Type 2 Diabetes

  2020cites this paper
• Diabetes Mellitus-How to Prevent Macrovascular Disease?

  2020cites this paper
• Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

  2019cites this paper
• Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators.

  2019cites this paper
• Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

  2019cites this paper
• The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.

  2019cites this paper
• DPP-4 Inhibition and the Path to Clinical Proof

  2019cites this paper
• A RANDOMIZED, OPEN LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF VILDAGLIPTIN AND METFORMIN COMBINATION VERSUS VILDAGLIPTIN ALONE IN TYPE 2 DIABETES MELLITUS PATIENTS IN A TERTIARY CARE HOSPITAL

  2019cites this paper
• More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

  2019cites this paper
• Universitet Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2

  2019cites this paper
• Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

  2018cites this paper
• A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials

  2018cites this paper
• A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2018cites this paper
• A Systematic Review on the Clinical Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients

  2018cites this paper
• Strategies and Research Progress of Chinese Medicine in Prevention and Treatment of Diabetic Peripheral Neuropathy

  2018cites this paper
• Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies.

  2018cites this paper
• DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes.

  2018cites this paper
• Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro

  2017cites this paper
• Cardioprotective Role of Saxagliptin through Antioxidant Mechanism in Experimental Myocardial Infarction in STZ Induced Diabetic Rats

  2017cites this paper
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

  2017cites this paper
• Combination treatment for type 2 diabetes mellitus (T2DM) : dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin

  2017cites this paper
• Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale

  2017cites this paper
• INHIBITORY POTENCY OF WITHANIA SOMNIFERA EXTRACTS AGAINST DPP-4: AN IN VITRO EVALUATION

  2017cites this paper
• The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration

  2017cites this paper
• Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance

  2017cites this paper
• Glucagon-like peptide-1 and glucagon-like peptide-1 analogs nanotechnology-based systems for prevention and therapy of diabetes

  2017cites this paper
• Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes

  2017cites this paper
• Cardioprotective Role of Saxagliptin through Antioxidant Mechanism in Experimental Myocardial Infarction in STZ Induced Diabetic Rats

  2017cites this paper
• DPP-4 Inhibitors

  2017cites this paper
• Synthesis and characterization of oxidovanadium complexes as enzyme inhibitors targeting dipeptidyl peptidase IV.

  2017cites this paper
• The Regulation of Release of Dipeptidyl Peptidase IV from Healthy and Diabetic Skeletal Muscle

  2017cites this paper
• Dipeptidyl peptidase-4 and kidney fibrosis in diabetes

  2016cites this paper
• Histoire des incrétines : Du chien brun au monstre de Gila

  2016cites this paper
• Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action

  2016cites this paper
• NUEVOS FÁRMACOS EN DIABETES MELLITUS

  2016cites this paper
• Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase‐4 inhibitor development

  2016cites this paper
• Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes

  2016cites this paper
• Molecular regulation of insulin granule biogenesis and exocytosis.

  2016cites this paper
• Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC-MS/MS and its application in a pharmacokinetics study.

  2016cites this paper
• Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

  2016cites this paper
• Prasanna Sakha Development of Microfluidic Applications to Study the Role of Kainate Receptors in Synaptogenesis

  2016influential citation
• Impaired pro-islet amyloid polypeptide processing promotes beta-cell dysfunction in diabetes and islet transplants

  2016cites this paper
• Dipeptidyl Peptidase-4 (DPP-4)-Inhibiting Amides for the Treatment of Diabetes

  2016cites this paper
• Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs.

  2015cites this paper
• Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors

  2015cites this paper
• The Role of Syntaxin-1a in Glucagon-like Peptide-1 Secretion from the Adult Mouse Intestinal L-Cell

  2015cites this paper
• The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

  2015cites this paper
• Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting

  2015cites this paper
• Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials

  2014cites this paper
• Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

  2014cites this paper
• Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors

  2014cites this paper
• Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors

  2014cites this paper
• PNS1300360 34..46

  2014cites this paper
• Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

  2014cites this paper
• Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.

  2014cites this paper
• Selective enrichment of bioactive properties during ultrafiltration of a tryptic digest of β-lactoglobulin

  2014cites this paper
• Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals

  2014cites this paper
• Specificity and sensitivity of commercially available assays for glucagon‐like peptide‐1 (GLP‐1): implications for GLP‐1 measurements in clinical studies

  2014cites this paper
• Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.

  2014cites this paper
• Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.

  2014cites this paper
• Safety, efficacy and weight effect of two 11β‐HSD1 inhibitors in metformin‐treated patients with type 2 diabetes

  2014cites this paper
• Incretins: Their physiology and application in the treatment of diabetes mellitus

  2014cites this paper
• Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

  2014cites this paper
• A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth

  2014cites this paper
• GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.

  2014cites this paper
• Diabetes , Metabolic Syndrome and Obesity : Targets and Therapy Emerging DPP-4 inhibitors : focus on linagliptin for type 2 diabetes

  2013cites this paper
• Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

  2013cites this paper
• Structure based lead optimization approach in discovery of selective DPP4 inhibitors.

  2013cites this paper
• A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

  2013cites this paper
• Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.

  2013cites this paper
• Bioassay-Guided Isolation of DPP-4 Inhibitory Fractions from Extracts of Submerged Cultured of Inonotus obliquus

  2013cites this paper
• Competing Influences Of The Tumor Microenvironment On CD26 And The Cancer Phenotype Of Colorectal Carcinoma Cells

  2013cites this paper
• Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

  2013cites this paper
• Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (Psidium guajava L.): a key to the beneficial effects of guava in type II diabetes mellitus.

  2013cites this paper
• Efeito do inibidor da DPP-IV sobre glicemia, glucagon, insulina, peptídeo C, GLP-1 e ácidos graxos livres após dietas isocalóricas de diferentes composições nutricionaisem pacientes diabéticos tipo 2 virgens de tratamento

  2013cites this paper
• Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study

  2013cites this paper
• Coming full circle in diabetes mellitus: from complications to initiation

  2013cites this paper